The Week in Review: DSM and Sinochem Launch Antibiotic JV

Royal DSM and Sinochem won regulatory approval to launch their JV, which calls for Sinochem to pay $291 million for 50% stake in DSM’s anti-infectives unit; Nycomed’s acquisition of Guangdong Techpool Biopharma and a direct sales model in China boosted Nycomed’s Q2 revenues; Merck Serono opened a China lab as part of its planned R&D hub in Beijing; SinoCubate launched as an incubator/investor in mainland China companies; and NexBio released positive data from a Phase II trial of a novel biologic that aims to both treat and prevent infection by all flu strains. More details…. Stock Symbols: (XAMS: DSM) (Xetra: MRK) (OTCBB: SBAT) Share this with colleagues:   var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.